Search company, investor...

hanse chemie GmbH

hansechem.com

About hanse chemie GmbH

Micronics, Inc. is a developer of near patient in vitro diagnostic products for disease diagnosis, prognosis and treatment monitoring. The Company employs a core patent estate in microfluidics -- the ability to miniaturize complex tests onto credit card size disposable devices. Per the company, tests that today take hours to days in a central laboratory environment are processed on a Micronics disposable device in seconds to minutes.

Headquarters Location

8463 154th Avenue NE, Building G

Redmond, Washington, 98052,

United States

Missing: hanse chemie GmbH's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: hanse chemie GmbH's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing hanse chemie GmbH

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

hanse chemie GmbH is included in 1 Expert Collection, including Health Monitoring & Diagnostics.

H

Health Monitoring & Diagnostics

702 items

Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting

hanse chemie GmbH Frequently Asked Questions (FAQ)

  • Where is hanse chemie GmbH's headquarters?

    hanse chemie GmbH's headquarters is located at 8463 154th Avenue NE, Building G, Redmond.

  • Who are hanse chemie GmbH's competitors?

    Competitors of hanse chemie GmbH include InPhenix, Mirabilis Medical, Novadaq Technologies, Freedom Meditech, Crescendo Bioscience, Micronics Microfluidics, Bg Medicine, PointCare Technologies, Nanogen, Kjaya and 12 more.

Compare hanse chemie GmbH to Competitors

N
Nanogen Adavanced Diagnostics S.r.l.

At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.

E
Expression Diagnostics

XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. Per the company, they have developed a proprietary method of utilizing gene expression in blood that aims to provide a new tool for physicians to manage the care of heart transplant patients. The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.

C
Cartesia DX

Cartesia Dx's first product, Arthritis Imager, addresses the lack of objective, quantifiable diagnosis and monitoring of Rheumatoid Arthritis (RA). The system combines well established technologies with a approach to create a new diagnostic metric that aims to allow healthcare professionals to objectively quantify the progression of RA. The Arthritis Imager uses a combination of Thermal and 3D imaging technologies to derive quantitative indicators to assess the severity of inflammation.

M
Modules for Novel Diagnostics

MND Diagnostics is a healthcare company focused on disease diagnosis. The medical device company has developed a diagnostic detection platform which aims to be rapid, low-priced and portable.

N
NeoDiagnostix

NeoDiagnostix develops molecular diagnostic and prognostic tests for the treatment of cancer. The company's test results eliminate the ambiguity experienced in millions of samples analyzed by traditional cytomorphology-based cell analyses. The company is committed to providing physicians with information that will improve patient care and treatment.

K
Kjaya

Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.